Surrozen, Inc. (SRZN) News
Follow Surrozen, Inc. (SRZN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Surrozen FDA clears IND for SZN-8141 in diabetic macular edema
REGULATION | Oct 02, 2026, 12:00 PM UTC
L
Surrozen Price Target Raised to $54.00/Share From $44.00 by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 12:04 PM UTC
H
Crude Oil Rises Over 4%; Darden Earnings Miss Views
U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 350 points on Thursday. The Dow traded down 0.70% to 51,153.35 while the NASDAQ dipped 0.70% to 26,746.39. The S&P 500 also fell, d
LIVE | Sep 24, 2026, 04:02 PM UTC
L
SRZN DUET study launches for dual VEGF/Wnt therapy in DME
A two-part clinical study for a dual VEGF/Wnt molecule in diabetic macular edema will start this year, focusing on safety, efficacy and unique reperfusion endpoints. Initial data is expected in 2027.
EQUITY | Sep 10, 2026, 03:04 PM UTC
L
SRZN: DUET study launches this year to test dual VEGF/Wnt therapy in DME, targeting clinical differentiation
The DUET clinical study will launch later this year, evaluating a dual VEGF/Wnt molecule in DME with Vabysmo as comparator, focusing on safety, durability, and unique reperfusion endpoints. Strong preclinical data, robus
EQUITY | Sep 10, 2026, 02:08 PM UTC
M
Surrozen submits IND application for SZN-8141 to treat diabetic macular edema
Surrozen says it has submitted an IND application for SZN-8141 for the treatment of diabetic macular edema.
EQUITY | Sep 08, 2026, 12:37 PM UTC
M
Surrozen submits IND application for SZN-8141 in diabetic macular edema
Surrozen (SRZN) announced it submitted an IND application for SZN-8141 for the treatment of diabetic macular edema.
EQUITY | Sep 08, 2026, 12:31 PM UTC
L
SRZN - Surrozen to Present at Upcoming Healthcare Investor Conferences
SRZN - Surrozen to Present at Upcoming Healthcare Investor Conferences
EQUITY | Sep 02, 2026, 08:05 PM UTC
L
SRZN gets Outperform call and $51 fair value from WBLR
Hammerstone MarketTalk reports SRZN is rated Outperform with a $51 fair value at WBLR; no further financial details or catalyst are provided.
EQUITY | Aug 20, 2026, 12:29 PM UTC
L
William Blair initiates SRZN at Outperform
William Blair initiates coverage of SRZN with an Outperform rating; no catalyst or valuation details were supplied.
EQUITY | Aug 20, 2026, 11:56 AM UTC